Conclusions:
We reliably quantified estrogens and glucocorticoids in breast adipose tissue 63 from healthy women and women suffering from breast cancer. Our findings suggest that 64 smaller breast tumors are associated with higher levels of estradiol and cortisol in adipose 65 tissue.
PRÉCIS 67
Estrogens and glucocorticoids were measured by LC-MS/MS in breast fat tissue from 68 women with or without breast cancer. Tumor size was negatively associated with estradiol 69 and glucocorticoid levels. 70
INTRODUCTION 72
Being overweight or obese is a well-known risk factor for postmenopausal breast cancer 73 1,2 . Obesity is also linked to a poorer prognosis in women with breast cancer regardless of 74 their menopausal status 1,3,4 . Women with obesity have more aggressive tumors, higher 75 mortality rates, incidence of metastases and increased risk of recurrence 1,5-8 . Central 76 obesity, as measured by waist circumference (WC), is an emerging risk factor for both pre-77 and postmenopausal breast cancer 9 . Furthermore, the efficacy of chemotherapy, 78 radiotherapy, surgery and endocrine therapy is reduced in women with obesity and possibly 79 more so with increased visceral fat accumulation [10] [11] [12] [13] [14] . The mechanisms underlying higher 80 risk and reduced treatment efficacy are not fully understood. Altered secretion of 81 adipokines, growth factors and steroids by dysfunctional mammary adipose tissue may 82 contribute to a pro-inflammatory, growth-promoting microenvironment for cancer cells 15 . 83
Recent evidence from human studies has shown that local breast adipose tissue does 84 present an altered biological profile, as described above, concomitant with body mass index 85 (BMI) increases [16] [17] [18] [19] [20] [21] . Reports from Iyengar and collaborators have showed that mean 86 adipocyte cell size from breast adipose tissue was positively associated with BMI, 87 increased aromatase expression and inflammatory markers such as crown-like structures 88 and was also related to menopausal status 19, 20 . 89 Expression and activity of several steroidogenic enzymes present in adipose tissue have 90 been linked to increased adiposity 22 . For example, higher rates of androgen-to-estrogen 91 conversion through aromatization in adipose tissue 22 have been proposed as a mechanism 92 for the obesity-related increase in breast cancer risk. Findings from our group suggest that 93 known estrogenic 17β-HSD (type 1, 7 and 12)-mediated conversion of estrone (E1) to estradiol (E2) is five times higher in differentiated adipocytes than in preadipocytes 23 . 95 Increased mean adipocyte size is associated with higher expression level and activity of 96 11β-HSD type 1 which locally converts cortisone to active cortisol through oxoreductase 97 activity 24, 25 . 98
Despite their well-known anti-inflammatory effects, glucocorticoids (GC) could contribute 99 to breast cancer initiation, progression and survival via the activation of the glucocorticoid 100 receptor (GR) or by increasing aromatase expression via the GC response element (GRE) 101 on exon I.4 of the CYP19A1 gene 26 . Moreover, 11β-HSD1 expression increases with 102 estrogen receptor β (ERβ) activation 27 . In a rodent model of breast cancer, increased GC 103 levels nurtured the transition from DCIS (ductal carcinoma in situ) to IDC (invasive ductal 104 carcinoma) while administration of RU-486 was able to partially block this effect, i.e. 105 prevent breast cancer progression to IDC 28 . Considering the slow turnover of GC in 106 adipose tissue 29 , there is biological plausibility for autocrine and paracrine effects of active 107 GC, such as cortisol, in the tumoral microenvironment. 108
Hence, steroid dynamics in breast adipose tissue and cancer appear to be involve more than 109 overexpression and increased activity of aromatase. We currently have very little 110 information about the relative importance of adipose tissue dysfunction markers such as 111 altered steroid conversion to tumor progression and aggressiveness or patient prognosis. 112
Moreover, considering the complexity of potential enzymatic hormone conversion in 113 adipose tissues, direct measurement of active hormone levels and their precursors has 114 become highly relevant. 115
Liquid-chromatography followed by tandem mass spectrometry (LC-MS/MS) is 116 recognized as the gold standard to quantify endogenous steroids in plasma, however, tissue steroids are harder to measure than those in plasma due to the complexity of the matrix and 118 the need to homogenize uniformly. Measurements are confounded by the low abundance 119 and the poor ionisation profile of steroids as well as the higher concentrations of lipids in 120 adipose tissue than in plasma, which result in higher susceptibility of so-called matrix 121 effects. We aimed to characterize the relationship of locally-produced cortisol and E2 as 122 well as inactive steroid cortisone and main E2 precursor E1, with adiposity and prognostic 123 markers in a sample of women with or without breast cancer. We hypothesize that 124 independently of menopausal status: i) E2 and cortisol breast adipose tissue levels as well 125 as the ratio E2/E1 and cortisol on cortisone are increased with adiposity; ii) worst clinical 126 breast cancer features, such as tumor stage, size and grade are associated with lower 127 adipose tissue steroid levels; and iii) estrogen relative amounts are increased in women 128 with ER+/PR+ tumors. We also investigated if these relationships were independent of 129 total adiposity i.e. reflecting the micro-environment or a characteristic of the adiposity 130 state. 131
METHODS

133
Study sample and data collection 134
The study protocol was approved by the Research Ethics Committees of Laval University 135
Medical Center (DR-002-136). All patients signed a written, informed consent prior to 136 surgery. Breast adipose tissue was obtained from women undergoing partial or total 137 mastectomy for treatment of breast cancer (n = 17) or reduction mammoplasty (n = 6). 138
Fresh tissue specimens were acquired from residual resected breast tissues that were not 139 required for clinical diagnosis at least 1 cm away from the tumor margins. Information on 140 clinicopathologic and anthropometric factors was collected from in-person interviews, 141 phone-call interviews and medical records. 142
Laboratory methods 143
Cell sizing 144
Breast adipocyte size was measured as previously described 30,31 in formalin-fixed adipose 145 tissue. Briefly, 250 breast adipocytes from 10 randomly chosen areas at × 40 magnification 146 using Calopix software (Tribvn) were measured for each subject, in a blinded fashion. 147 Waters, Wilmslow, UK; MeOH (2 x 10 mL), followed by H2O (2 x 10 mL)). The adipose 179 extract was loaded, and the column was washed with H2O (10 mL) followed by aqueous 180
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 148
Standards and solvents
MeOH (5%, 10 mL). Steroids were eluted with MeOH:CH3CN (1:1, 10 mL). The eluent 181 was dried down under OFN at 60°C prior to derivatization of estrogens. Generation of 1-182
(2,4-dinitrophenyl)-4,4-dimethylpiperazinium (MPPZ) derivatives of E1 and E2 has 183 already been described [32] [33] [34] . Derivatization was carried out by incubating (1h, 60°C) with 184 (CH3)2CO (70 µL), NaHCO3 (10 µL, 1M, Sigma-Aldrich, Inc (St-Louis, USA)) and PPZ 185 (10 µL, 1 mg/mL, dissolved in (CH3)2CO) followed by addition of CH3I; (100 µL) and 186 further incubation (2h, 40°C) as previously described 33, 34 . Samples were dissolved in 187 H2O:CH3CN (70 µL; 70:30) and transferred to LC vials. 188
Liquid chromatography parameters 189
Following injection (30 µL), analytes were separated on an ACE 2 Excel C18-PFP 190 (150 × 2.1 mm, 2 μm; HiChrom, Reading, England, 40°C) column. The elution process 191 started with mobile phase compositions of 90:10 H2O with 0.1% FA (solution A) and 192 CH3CN with 0.1% FA (solution B) which was maintained for 1 minute. This was followed 193 by an 11-minute linear gradient to 50% solution B, which was maintained for 2 minutes, 194 before returning to 10% solution B at 15 minutes and maintained for 3 minutes, all at a 195 constant flow rate of 0.5 mL/min. 196
Linearity and lower limit of quantitation (LLOQ) 197
Blank samples and aliquots containing estrogens (5, 7.5, 10, 15, 25, 50, 100, 200, 500, 198 IS (500 pg) were analysed by LC-MS/MS. Calibration curves were plotted as the peak area 200 ratio (standard/IS) versus amount of analytes (GC or estrogens). Calibration lines of best 201 fit were acceptable if the regression coefficient, r, was > 0.98. Weightings of 1/x were used 202 for all four steroids. LLOQs were 50 pg, 15 pg, 100 pg and 75 pg for E2, E1, cortisol and 203 cortisone, respectively. Values below the confirmed LLOQ were calculated as LLOQ 204 divided by 3 i.e. the lowest acceptable signal-to-noise ratio. The values were then converted 205 to pmol/kg according to the weight of the corresponding adipose tissue sample. This 206 transformation was performed to avoid null values to calculate steroid ratios as described 207 below. 208
Calculated ratios 209
All steroid amounts were converted into pmol/kg. Those values were then used to calculate 210 product and substrate ratios, as described below. The ratio of cortisol:cortisone was used 211 as a marker of 11β-HSD1 enzyme activity. The ratio of E2:E1 was used as a marker of 212 estrogenic 17β-HSD enzyme activity. 213
Gene expression 214
Tissues were homogenized in Qiazol buffer (Qiagen, Germantown, MD, USA) and total 215 RNA was extracted using the RNeasy mini kit on-column DNase ( 
RESULTS
260 Table 2 shows the characteristics of the study sample. Women were overweight with a 261 median BMI of 25.6 kg/m 2 and a median age of 55 years. Postmenopausal status was 262 equally balanced across case and control women. Table 3 presents the clinicopathological  263 features of pre-menopausal and post-menopausal breast cancer patients. Most women 264 presented with a unilateral breast lesion. Breast tumors were mainly of ductal histology 265 (82%). Only one woman presented a HER2+ tumor and 13 women had an ER+/PR+ tumor. 266
Half of the women had stage 2 breast cancer as classified by TNM score 35 . 267 Women with or without breast cancer were comparable for primary clinical characteristics, 268 except for mean fat cell size which was 13.3 µm higher in the control women (t-test, 269 P = 0.0072). This difference was also shown by the adipocyte size distribution curve 270 comparison (KS, P = 0.0041) ( Figure 1A) . Postmenopausal women had a 9.7 µm higher 271 mean adipocyte size compared to premenopausal women as well as a right-shifted 272 adipocyte size distribution, however this difference was not statistically significant ( Figure  273 1B). The distribution remained similar when considering only cancer cases ( Figure 1C) . 274 Table 4 shows adipose tissue steroid relative amounts and calculated ratios. E1 and cortisol 276 relative amounts were quantified in each of the 23 samples of mammary adipose tissue. E2 277 level was below the limit of quantification for 2 samples. Cortisone level was below the 278 limit of quantification for 5 samples, 4 of which were obtained from control women. 279 11β-HSD1 mRNA abundance was positively correlated with the cortisol:cortisone ratio 280 (r = 0.4929; P = 0.0198) and negatively associated with the cortisone relative amount (r = -0.4850; P = 0.0221). In women with ER+/PR+ tumor, 17β-HSD12 transcript amount 282 (r = 0.5804; P = 0.0479) was correlated with E1 relative amount in breast adipose tissue. 283 17β-HSD12, 17β-HSD7 or CYP19A1 were not correlated with E2 relative amount. 284
Quantification of steroids 275
Women with cancer had higher expression level of 17β-HSD12 mRNA compared to 285 controls (P = 0.0231). E2 relative amount was positively associated with ERβ mRNA 286 expression (r = 0.6083, P = 0.0358), but not ERα mRNA expression in women with 287 ER+/PR+ tumor. In women with breast cancer, abundance of CYP19A1 transcript was 288 positively correlated with 11β-HSD1 mRNA expression (r = 0.5353, P = 0.0326). 289
Adiposity 290
The ratio of E2 to E1 was higher in lean women compared to women with a BMI ≥ 25 291 kg/m 2 (P = 0.0335) (Figure 2A) (postmenopausal, n=15, P=0.0072; premenopausal, n=8, 292 P=NS) in the entire cohort, even if CYP19A1 expression was higher in women with a 293 BMI ≥ 25 kg/m 2 (p<0.05). This difference remained significant when considering only 294 cancer cases (P = 0.0393, n = 17), or only ER+/PR+ patients (P = 0.0436, n = 13). The 295 difference, although the same magnitude as above, was no longer statistically significant 296 when considering ER+/PR+ patients with invasive carcinoma (stage ≥ 1) (P = 0.0900, 297 n = 11). E2 levels were higher in lean women than in overweight and obese women in 298 cancer cases (P = 0.0494) ( Figure 2B) (postmenopausal, n=11, P=0.0325; premenopausal, 299 n=6, P=NS). cancer cases (P = 0.0494) (Figure 2B) . There was no difference in levels of 300 cortisol and cortisone between lean and overweight/obese women (data not shown). 301
Breast cancer clinical features 302
Adipose tissue E2 level (log-transformed) was inversely associated with tumor size 303 (categorical variable) ( Figure 3A) (P = 0.0281, n = 17) (postmenopausal, n=11, P=0.0283; premenopausal, no convergence), but this relationship did not reach statistical significance 305 when tumor size was treated as a continuous variable (β = -0.0199, P = 0.1089, n = 17). 306
Further adjustment for menopausal status and use of hormonal derivatives did not alter the 307 results (P = 0.0488, n = 17) whereas the relationship was no longer significant after 308 adjusting for BMI (P = 0.1569, n = 17) or when considering only patients with invasive 309 carcinoma (stage ≥ 1) (P = 0.1157, n = 14). Including only women with ductal carcinoma 310 generated similar effect size. Although the adjusted models were no longer significant, the 311 non-adjusted model remained significant (data not shown). CYP19A1 mRNA expression 312 level was positively correlated with tumor size (r = 0.4875, P < 0.05), whereas expression 313 of ERα mRNA was negatively associated with this variable (r = -0.5435, P = 0.0296). 314
There was no relationship between adipose tissue estrogen levels and tumor stage or tumor 315 grade in our sample. 316
The ratio of cortisol to cortisone was lower in women with cancer compared to control 317 women (P < 0.0001). This difference was driven by higher cortisone levels and not lower 318 cortisol levels. In fact, cortisone levels were higher in cancer patients than in control 319 patients (P = 0.0055). These differences remained when combining controls with women 320 with ER-/PR-breast cancer, who shared similar characteristics ( Table 5) , and comparing 321 them to women with ER+/PR+ tumor (P = 0.0097 and P = 0.0171, respectively) (data not 322 shown). 323
No difference was detected between control women and cancer-positive women with 324 respect to cortisol (data not shown). Both log-transformed cortisol and cortisone levels 325 were inversely associated with tumor size [(β = -0.01873, P = 0.0007) and (β = -0.05048, 326 P < 0.0001)] independent of BMI, menopausal status and current use of hormonal derivatives [(β = -0.02135, P = 0.0027) and (β = -0.03636, P < 0.0001)] (Figure 3BC ) 328 when tumor size was treated as a continuous variable. When we stratified according to 329 menopausal status, the mixed-models remained significant for postmenopausal women 330 (n=11) (Figure 3BC ; P=0.0055, P<0.0001) but did not converge for premenopausal 331 women (n=6). Those relationships were still significant when including only patients with 332 invasive tumors [Cortisol: (β = -0.02376, P = 0.0078); (βadj = -0.02977, P = 0.0079) and 333
Cortisone (β = -0.03328, P < 0.0001); (βadj = -0.03650, P < 0.0001)]. Contrary to 334 estradiol, cortisone and cortisol were not associated with tumor size (all TNM stages 335 included or with only invasive tumors) (P = 0.0904 and P = 0.1894). Tumor stage was 336 negatively associated with cortisol/cortisone ratio independent of BMI (β2 = -1.8720, 337 β3 = -1.8316; P = 0.0410) ( Figure 3D) A limitation of that study is the lack of data regarding normal breast adipose tissue from 362 healthy controls. In vitro uptake of E1, E2 and cortisol from culture media by female 363 abdominal adipose tissue explants was reported as more than two-fold lower compared to 364 progesterone and testosterone, highlighting the possible contribution of steroid conversion 365 in adipose tissue as a source of estrogens and GC for the tumor 45 . 366
Quantification of steroids 367
We have been able to quantify these four steroids in most of our breast adipose samples. 368
Interestingly, we found similar ranges in relative amounts for estrogens as those reported 369 by Honma and collaborators in breast cancer tissue, using LC-MS/MS 46 . These findings suggest that breast adipose tissue is a potent source of sex hormones for the tumor. One of 371 the strengths of our study is the use of stable isotope dilution LC-MS/MS instead of the 372 historically used ELISAs (enzyme-linked immunosorbent assay). ELISAs for steroid 373 measurements have several drawbacks such as nonspecific antibody interactions, 374 inconsistent reproducibility and inadequate sensitivity 47 . Moreover, they usually require 375 separate assays for each compound of interest, demanding a large quantity of tissue. Using 376 three stable isotope labelled standards in our protocol allowed us to normalize for loss of 377 analytes during the extraction process. 378
Contrary to our hypothesis, our data, reported as pmol/kg of whole adipose tissue, showed 379 a decrease in the ratio of E2/E1 and a decrease of E2 with increasing adiposity, as assessed 380 with the BMI, suggesting little impact of aromatase conversion per mass unit in adipose 381 tissue. This can also be explained by the higher affinity of androstenedione as a substrate 382 for aromatase compared to testosterone, as previously reported 48 . Marchand et al. reported 383 that higher circulating E2 level is directly associated with increased fat mass 49 . Simpson 384 et al. reported that increased aromatization in obesity was due to a higher number of cells 385 and not to higher conversion activity per adipose tissue mass unit 50 . Our results are also 386 consistent with another study where the authors found a positive correlation between E1/E2 387 ratio from visceral fat and BMI in postmenopausal women 51 . Contrary to Savolainen-388 Peltonen, we found that 17β-HSD type 12 mRNA expression is higher in adipose tissue 389 from cancer patients compared to controls 43 . We cannot exclude that the lower levels of 390 E2 observed in adipose tissue of overweight and obese women are due to increased uptake 391 by the tumor cells as previously proposed by Savolainen-Peltonen 43 . However, we 392 observed this difference in our entire sample and with all women with cancer, including those with ER-status. Effect size were not modified when stratification by ER+/PR+ was 394 performed. 395
We were unable to find a significant association between BMI and cortisol levels in breast 396 adipose tissue. We acknowledged that this may be due to our limited sample size. However, 397
we found lower and non-quantifiable cortisone levels in breast adipose tissue of our control 398 women (4 out of six). Our group of control women had higher mean adipocyte size than 399 our women with cancer. This is not surprising, as our control women tended to have higher 400 BMI than the women with cancer, although not statistically significant probably because 401 of our small sample. The adipocyte size difference reported between pre-and post-402 menopausal women is similar to the findings of Iyengar and collaborators 19 . The lower 403 levels of cortisone could be partially explained by a higher activation rate of cortisol or a 404 lower inactivation of cortisol to cortisone by 11β-HSD1, because our gene expression 405 results suggest that 11β-HSD1 expression is positively associated with the 406 cortisol:cortisone ratio and negatively associated with the cortisone relative amount These 407 results are consistent with previous findings from our team which showed that 11β-HSD1 408 activity and expression is positively associated with adipocyte size, at least in the 409 abdominal subcutaneous and omental depots 24, 25 . A previous study with obese subjects 410 undergoing bariatric surgery has indeed found lower levels of cortisone in adipose tissue 411 of obese subjects before weight loss and when compared to control with no difference in 412 adipose tissue cortisol levels among those groups 52 . No difference in tissue relative amount 413 of cortisol could be explained by concomitant higher clearance by 5α-reductase, also 414 increased in obesity 53 . However, our data showed no decrease of cortisone with higher BMI which suggests a different catabolism of cortisol and cortisone in women with breast 416 cancer. 417 Some steroids were previously proposed to be increased in adipose tissue during obesity 418 such as cortisol, which could also act as an immune suppressor in breast tissue. As reported 419 by Cirillo et al., many different tumor types produce active cortisol which inhibits tumor-420 specific CD8+ T proliferation in vitro 54 . Infiltration of CD8+ cells was linked to improved 421 cancer-specific survival by Mohammed and collaborators 55 . However, breast cancer was 422 one of the types of cancer not showing any difference between 11β-HSD1/2 expression 423 between cancer and matched normal epithelial tissues, which suggest a paracrine, possibly 424 by adjacent adipose tissue instead of an autocrine effect by cortisol 54 . In the same order of 425 ideas, immunohistochemistry of 11β-HSD1 showed a presence of the enzyme in 64% of 426 breast tumors and 97% of matched adjacent tissue 56 and GR protein level was higher in 427 breast tumor vs normal epithelial tissue 57 . Increases in GC, particularly cortisol, can induce 428 aromatase expression via the GRE on exon I.4 26 . On the other hand, cortisol via binding 429 to GR is an activator of the estrogen sulfotransferase, which inactivates estrogens by adding 430 a sulfate group and limiting its binding to ER 58 . 431
We did observe higher cortisone levels in adipose tissue from women with cancer with no 432 change in cortisol. As per our initial hypothesis, we did observe a decrease of estradiol, 433 cortisol and cortisone adipose tissue levels according to tumor size and a decrease of 434 cortisol/cortisone ratio with increasing tumor stage. As stated previously, the decrease of 435 estradiol, but not estrone with tumor size could represent an increased uptake by the tumor 436 cells 42 . The higher cortisol/cortisone ratio between cancer patients in comparison to control 437 women and the further decrease of this ratio with tumor stage point to a dual effect of glucocorticoids in breast cancer related to stage of the disease. Increases in 439 cortisol/cortisone ratio at the lower stages could increase estrogen production via activation 440 of aromatase, but at a later stage, decreases in cortisol/cortisone could be explained by a 441 negative feedback loop through increased estrogen production by the tumor and a 442 concomitant lower expression of 11β-HSD1. However, we were unable to demonstrate a 443 relationship between cortisol/cortisone ratio with E2/E1 ratio or E2 and E1 in our sample, 444 contrary to previous results in visceral adipose tissue, but similar to results in subcutaneous 445 tissue 51 . 446 Despite our relatively low number of patients in both groups, we found that median E2 447 adipose tissue level was higher in women ER+/PR+ than ER-/PR-. Hennig et al. reported 448 higher adipose tissue E2, androstenedione and androsterone levels in women with ER+ 449 breast cancer compared to ER-, but no difference in E1 or any of the other androgens and 450 progestagens 44 . Falk et al. measured sex steroids by radioimmunoassay and found a 451 significant difference only for testosterone and a trend for higher E2, E1 and 452 androstenedione adipose tissue levels in ER+/PR+ compared to ER-/PR-samples 40 . We 453 found that E2 relative amount was associated with ERβ mRNA, but not that of ERα in 454 women with ER+/PR+ tumor. ERβ expression is known to be increased with E2 455 production, not ERα, either suggesting a negative feedback or no effect depending on depot 456 origin 59 . ERβ is only expressed in mature adipocytes in adipose tissue whereas ERα is 457 present in both the stroma-vascular fraction and in mature adipocytes 60 . Lower ERα 458 expression has been linked with adipose tissue dysfunction 61 . However, a relationship with 459 adipocyte cell size and ERα expression level was not observed in our study.
Limitations of our study comprised the relatively low number of participants which is 461
counterbalanced by the wide range of BMI and prognostic marker values of our cohort. Of 462 note, our total sample number is in the same order of magnitude compared to previous 463 literature on breast adipose tissue steroid measurements [40] [41] [42] [43] premenopausal women (n=6 out of 51) in their analyses. They did not, however, separate 470 according to menopausal status due their low number of premenopausal women. We 471 acknowledge the potential difference in hormone metabolism between pre-and 472 postmenopausal women. Because the main source of estrogens shifts from gonads to 473 peripheral tissues in menopause, we adjusted for menopausal status and age in our analysis. 474
We also performed stratification to further alleviate concerns about the influence of 475 menopausal status, but these analyses should be interpreted with caution. It should be noted 476 that inference in our study is limited to postmenopausal women, as our number of 477 premenopausal women did not allow us to investigate fully their steroid concentration as a 478 separate group. Most of our findings were still significant when including only 479 postmenopausal women. Of note, tissue steroid concentration in our study did not vary as 480 a function of menopause. Our cohort represents normal demographics in breast cancer, i.e. 481 increased prevalence in older, postmenopausal women. Hence, we suggest that these 482 findings are relevant in this context. The use of a cross-sectional design does not allow for causal inferences and we 484 acknowledge that there might be reverse causality as higher tumor stage and size may cause 485 changes in steroid metabolism rather than the opposite. Another constraint is that we cannot 486 quantify the distance from the tumor at which the adipose tissue samples were taken. 487
However, as the defined margins were all included in paraffin blocks for 488 clinicopathological assessment directly at the hospital, we can attest that our adipose 489 samples were taken at least 1 cm from the tumor extremities. Hennig et al reported no 490 difference between steroid levels between two sample locations (less than 0.5 cm and more 491 than 5 cm), except for E2 44 . Due to standard of care and acceptable limit margins in 492
Quebec for clinicopathological assessment, it was not possible to include adipose tissue 493 less than 0.5 cm away from the tumor in a research project. Therefore, the variation of E2 494 due to the relative distance from the tumor was likely limited. 495 CONCLUSION 497 We were able to quantify estrogens and glucocorticoids in breast adipose tissue from both 498 healthy women and women suffering from breast cancer. There is clear indication that 499 steroid hormone metabolism is different among those two subgroups. Moreover, relative 500 amounts of sex steroids in adipose tissue appear to be related to BMI, especially for E2, 501
whereas differences in glucocorticoids levels appear to be more closely related to cancer 502 progression. As such, estradiol levels were lower in women with larger tumors 503 independently of age and menopausal status and glucocorticoid breast adipose tissue levels 504 were negatively associated with tumor size, independently of age, menopausal status and 505 BMI. 506 
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